Pharmedium Recalls Dexamethasone Sodium Phosphate Infusions Due to Sterility Concerns
Pharmedium Services, LLC is recalling Dexamethasone Sodium Phosphate added to 5% Dextrose nationwide due to a lack of sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. Under the severity rubric, an FDA Class II recall involving a significant hazard such as lack of sterility assurance in an injectable drug corresponds to a score of 4 (Severe), particularly given the potential for serious injury from non-sterile medical products.
Plain-English summary
Pharmedium Services, LLC is recalling Dexamethasone Sodium Phosphate added to 5% Dextrose in all strengths, doses, and packaging. The recall is being conducted because of a lack of sterility assurance in the product.
The affected product is distributed nationwide in the United States. The recall includes all lots that remain within their expiration dates. The source text does not specify the number of units affected or report any specific illnesses or injuries.
Consumers and healthcare providers should stop using the recalled product and contact their pharmacist or the recalling firm for further instructions on disposal or replacement.
The recalled product
- Product
- Dexamethasone Sodium Phosphate added to 5% Dextrose in all strengths, all doses, and all packaging.
- Manufacturer
- Pharmedium Services, LLC
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots remaining within expiry.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 42 recalled by Pharmedium Services, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 42 products in this recall →Related recalls
Same manufacturer · Pharmedium Services, LLC
See all →- SeverePharMEDium Recalls nICARdipine HCl Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls ePHEDrine Sulfate Syringes Due to Sterility Assurance Issues
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls Fentanyl Citrate Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls Fentanyl Citrate Infusions Due to Sterility Assurance Issues
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls Rocuronium Bromide Syringes Due to Sterility Assurance Issues
FDA (Drugs) · 2020-04-15
Same hazard · lack of sterility
See all →- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
Similar recalls
- SeverePharMEDium Recalls Potassium Phosphate Injection Due to Sterility Concerns
FDA (Drugs) · 2017-07-26
- SevereDexamethasone phosphate injection recalled for lack of sterility assurance
FDA (Drugs) · 2014-03-12
- SevereGreen Valley Drugs Recalls Dexamethasone Sodium Phosphate Injection Due to Sterility Concerns
FDA (Drugs) · 2013-05-22
- SevereDexamethasone Solution Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2014-01-22
- SevereMorphine Sulfate Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2022-01-05
- SevereGreen Valley Drugs Recalls Betamethasone Sodium Phosphate Injection Due to Sterility Concerns
FDA (Drugs) · 2013-05-22